Brazilian experts recommend early genetic testing for people with ALS
Original source
Update and recommendations on genetic testing for amyotrophic lateral sclerosis in clinical practice: a Brazilian expert view. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Study type
- Review
- Studied in
- Human
A review by Brazilian ALS specialists recommends timely genetic testing as part of standard clinical care for people with amyotrophic lateral sclerosis (ALS). The authors say testing can support genetic counselling, identify relatives who may be at risk, help predict gene-specific disease courses and determine eligibility for some gene-targeted treatments.
Why this matters
This recommendation may affect discussions between people with ALS, their families and clinicians about whether and when to seek testing. The review identifies tofersen for SOD1-associated ALS as an example of a gene-targeted therapy and ulefnersen for FUS-associated ALS as a treatment under clinical investigation. Testing does not itself establish that a treatment will work for an individual.
Limitations and context
This is a review presenting the perspective of Brazilian neurologists who specialise in ALS care, not a new clinical trial. The source does not report a new patient cohort or quantify how testing changes outcomes, and its recommendations may not apply identically in every healthcare system. The source describes ulefnersen as still under clinical investigation.